JARDIANCE MET 12.5MG/1000MG Tablets (Empagliflozin + Metformin)
JARDIANCE MET 12.5MG/1000MG TABLETS contain Empagliflozin 12.5mg and Metformin 1000mg, a prescription antidiabetic combination used with diet and exercise to improve type 2 diabetes control.
JARDIANCE MET 12.5MG/1000MG TABLETS
JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN 12.5MG + METFORMIN 1000MG): Comprehensive Guide and Benefits
Introduction to JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN 12.5MG + METFORMIN 1000MG)
JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN 12.5MG + METFORMIN 1000MG): A Diabetes Medication (SGLT2 Inhibitor + Biguanide Combination)
JARDIANCE MET 12.5MG/1000MG TABLETS contain a fixed-dose combination of Empagliflozin 12.5mg and Metformin Hydrochloride 1000mg, belonging to the oral antidiabetic medication class. It is prescribed along with diet and exercise to improve blood glucose control in adults with type 2 diabetes mellitus.
Empagliflozin belongs to the SGLT2 inhibitor class and helps reduce blood glucose by increasing urinary glucose elimination, while Metformin is a biguanide that reduces glucose production in the liver and improves insulin sensitivity. JARDIANCE MET is a prescription-only medicine and should be used under medical supervision with appropriate monitoring.
Key Benefits of JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN + METFORMIN)
Helps improve blood sugar control in adults with type 2 diabetes.
Provides dual-action glucose lowering through complementary mechanisms.
Helps reduce excess glucose production and increase glucose removal.
Supports improved insulin sensitivity and glucose utilization.
Offers a convenient combination therapy option when prescribed.
How JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN + METFORMIN) Works
JARDIANCE MET combines two antidiabetic medicines with different mechanisms of action. Empagliflozin selectively inhibits sodium-glucose cotransporter-2 (SGLT2) in the kidneys, reducing glucose reabsorption and increasing glucose excretion through urine. Metformin decreases glucose production in the liver, improves peripheral insulin sensitivity, and reduces intestinal glucose absorption. Together, these actions help regulate blood glucose levels in patients with type 2 diabetes.
Usage Instructions for JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN + METFORMIN)
Take JARDIANCE MET exactly as prescribed by your doctor.
Swallow the tablet whole with water; do not crush, chew, or break it.
Take it at the recommended time, usually with meals if advised to improve stomach tolerance.
Monitor blood glucose levels and kidney function as recommended.
Do not stop or change the dose without medical guidance.
Medicinal Advantages of JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN + METFORMIN)
Helps achieve better glycemic control in type 2 diabetes management.
Combines two established oral diabetes medicines in one tablet.
Helps improve insulin response and reduce excess glucose levels.
Supports individualized diabetes treatment plans.
Provides a clinically established combination therapy option.
NOTE: JARDIANCE MET 12.5MG/1000MG TABLETS are prescription-only medicines. They are not used for type 1 diabetes and require monitoring of kidney function. Patients should inform their doctor about kidney disease, dehydration, recurrent infections, or other medical conditions before use.
Off-Label Uses of JARDIANCE MET 12.5MG/1000MG TABLETS (EMPAGLIFLOZIN + METFORMIN)
Healthcare professionals may occasionally consider components of this combination for uses outside approved indications based on clinical evaluation and available evidence.
Specialist-guided metabolic management approaches.
Selected insulin resistance-related conditions.
Individualized diabetes-related treatment strategies.
Disclaimer: Off-label uses should only occur under physician supervision and may not be approved in all countries.
Expert Advice for Optimal Use
Take JARDIANCE MET regularly as prescribed.
Maintain a balanced diet and exercise routine recommended by your healthcare provider.
Monitor blood glucose levels regularly.
Maintain adequate hydration unless fluid restriction is advised.
Inform your doctor before surgery or prolonged fasting.
Report symptoms of urinary infections, dehydration, or unusual weakness promptly.
Precautions
Cardiovascular Health
Patients with cardiovascular disease or risk factors should inform their healthcare provider. Diabetes management requires regular cardiovascular assessment and monitoring.
Liver & Kidney Function
Kidney function should be assessed before and during treatment when clinically required. Metformin may not be suitable for patients with severe kidney impairment. Liver health should also be discussed with a healthcare professional.
Pregnancy & Breastfeeding
JARDIANCE MET should be used during pregnancy only if specifically recommended by a healthcare professional. Breastfeeding women should consult their doctor before use.
Drug Interactions
JARDIANCE MET may interact with insulin, sulfonylureas, diuretics, contrast imaging agents, and other medicines affecting kidney function or blood glucose levels. Inform your doctor about all medicines and supplements.
Existing Medical Conditions
Inform your healthcare provider if you have kidney disease, liver disease, heart failure, recurrent urinary infections, dehydration, metabolic disorders, or a history of diabetic ketoacidosis.
Storage Instructions
Store below 30°C.
Keep tablets in the original blister packaging.
Protect from moisture and direct sunlight.
Keep out of reach of children.
Do not use after the expiry date.
Frequently Asked Questions (FAQs)
Q: What is JARDIANCE MET 12.5MG/1000MG TABLETS used for?
A: JARDIANCE MET 12.5MG/1000MG TABLETS are used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.
Q: What are the active ingredients in JARDIANCE MET?
A: The active ingredients are Empagliflozin 12.5mg and Metformin Hydrochloride 1000mg.
Q: Is JARDIANCE MET an insulin medicine?
A: No. It is an oral antidiabetic combination containing an SGLT2 inhibitor and a biguanide medicine.
Q: How does JARDIANCE MET lower blood sugar?
A: Empagliflozin removes excess glucose through urine, while Metformin reduces glucose production in the liver and improves insulin sensitivity.
Q: Can JARDIANCE MET cause low blood sugar?
A: Low blood sugar risk may increase when it is combined with insulin or certain other diabetes medicines. Consult your doctor if symptoms occur.
Q: Can JARDIANCE MET be stopped suddenly?
A: Do not stop JARDIANCE MET without medical advice, as blood glucose levels may increase.
Q: Is JARDIANCE MET available without prescription?
A: No. JARDIANCE MET is a prescription medicine and should be used only under healthcare professional supervision.
Product Tags
JARDIANCE MET 12.5MG/1000MG TABLETS, Empagliflozin 12.5mg Metformin 1000mg, Empagliflozin Tablet, Metformin Tablet, SGLT2 Inhibitor, Biguanide Medicine, Diabetes Medication, Type 2 Diabetes Treatment, Blood Sugar Control Tablet, Antidiabetic Medicine, Oral Diabetes Medicine, Glycemic Control Therapy, JARDIANCE MET Tablet, Empagliflozin Metformin Combination, Prescription Diabetes Medicine, Glucose Lowering Medicine, Diabetic Care Tablet, Type 2 Diabetes Management, Cardiometabolic Health Medicine, Diabetes Treatment Tablet.
